menu
    • menu

    Company profile for Qurient

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through ...
    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Qurientkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    C-dong 801, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13487, Korea
    Telephone
    Telephone
    +82-31-8060-1600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.qurient.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lonza's Synaffix Partners Qurient Therapeutics For Dual-Payload
    Lonza's Synaffix Partners Qurient Therapeutics For Dual-Payload

    25 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lonzas-synaffix-collaborates-with-qurient-therapeutics-to-enable-development-of-dual-payload-adc-302566442.html

    PR NEWSWIRE
    25 Sep 2025
    Share Share
    Qurient Launches AML Trial With Adrixetinib (Q702)
    Qurient Launches AML Trial With Adrixetinib (Q702)

    24 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024615775/en

    BUSINESSWIRE
    24 Oct 2024
    Share Share
    Korea's Qurient inks agreement with TB Alliance for new anti-tuberculosis agent
    Korea's Qurient inks agreement with TB Alliance for new anti-tuberculosis agent

    06 Feb 2023

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/26/21886/koreas-qurient-inks-agreement-with-tb-alliance-for-new-anti-tuberculosis-agent.html

    BIOSPECTRUM ASIA
    06 Feb 2023
    Share Share
    Qurient and TB Alliance Announce Exclusive License Agreement for Telacebec
    Qurient and TB Alliance Announce Exclusive License Agreement for Telacebec

    03 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/qurient-co-ltd-and-tb-alliance-announce-exclusive-license-agreement-for-telacebec-q203-a-new-anti-tuberculosis-agent-301738149.html

    PR NEWSWIRE
    03 Feb 2023
    Share Share
    Qurient Announces Dosing of First Patient in Q702 with KEYTRUDA in Ph1b/2 Study
    Qurient Announces Dosing of First Patient in Q702 with KEYTRUDA in Ph1b/2 Study

    30 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230202005011/en

    BUSINESSWIRE
    30 Jan 2023
    Share Share
    Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study
    Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study

    01 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221123005365/en

    BUSINESSWIRE
    01 Dec 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search